The Fluid Biomarker Program brings new expertise to research efforts for Alzheimer’s disease and other diseases. Finding simpler, easier and less costly ways to evaluate a person’s risk is important for both care and research. Getting an accurate early diagnosis could allow people earlier access to drugs - for example, those recently approved to treat Alzheimer’s disease - or allow for a more patient-centric management model. In addition, such tests could help researchers conduct clinical trials more effectively to assess potential new treatments and hypotheses that may slow disease progression.
The discovery biomarker program focuses on identifying new molecules in spinal fluid and blood that are related to cognitive and movement disorders and may be candidates for new tests. The Michael T. Zuendel Family Biomarker Laboratory also provides high-quality assessments of various spinal fluid and blood tests from national and international research studies and trial - characterizing and comparing their performance and using them to help improve the understanding, diagnosis, treatment, and prevention of these diseases. The ultimate aim is to fast-track scientific discovery into tests that benefit patients, all under one roof.
To learn more about our program, please call 623-832-6628.
Sign in to Patient Account
